Timothy Price, MBBS, DHthSc, FRACP, discusses the rationale to evaluate sotorasib in gastrointestinal cancers.
Timothy Price, MBBS, DHthSc, FRACP, senior consultant medical oncologist and director of Medical Oncology and Clinical Cancer Research at The Queen Elizabeth Hospital in Adelaide, discusses the rationale to evaluate sotorasib (AMG 510) in gastrointestinal (GI) cancers.
Findings from the phase 2 CodeBreak 100 trial (NCT03600883), which were presented during the ESMO Asia Virtual Congress 2020, demonstrated signals of disease control and a tolerable safety profile with sotorasib in heavily pretreated patients with KRAS G12C–mutant GI cancers.
Ultimately, the lack of targeted therapy options served as the basis for the CodeBreak 100 study, says Price. To date, no RAS-specific targeted therapies have been approved for patients with GI cancers, Price explains. However, options are available for patients with RAS wild-type, EGFR-mutant, and HER2-mutant GI cancers like colorectal cancer and non–small cell lung cancer.
Sotorasib targets KRAS G12C, Price says. Although other studies have evaluated novel targeted therapies, targeting KRAS G12C remains an area of unmet need in GI cancers, concludes Price.